Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients.

Guarneri, V; Dieci, M V; Barbieri, E; Piacentini, F; Omarini, C; Ficarra, G; Bettelli, S; Conte, P F

Guarneri, V; Dieci, M V; Barbieri, E; Piacentini, F; Omarini, C; Ficarra, G; Bettelli, S; Conte, P F.

Affiliation

Guarneri V; Istituto Oncologico Veneto IRCCS, University of Padova, Italy.

Ann Oncol ; 24(12): 2990-4, 2013 Dec.

Article in En | MEDLINE | ID: mdl-24013581

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Breast Neoplasms/metabolism; Carcinoma, Ductal, Breast/metabolism; Neoplasm Recurrence, Local/metabolism; Receptor, ErbB-2/metabolism; Adult; Aged; Aged, 80 and over; Anthracyclines/administration & dosage; Breast Neoplasms/mortality; Breast Neoplasms/therapy; Carcinoma, Ductal, Breast/mortality; Carcinoma, Ductal, Breast/therapy; Chemotherapy, Adjuvant; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local/prevention & control; Paclitaxel/administration & dosage; Prognosis; Prospective Studies; Treatment Outcome

Key words

HER2 change; breast cancer; discordance; primary systemic therapy; trastuzumab

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Carcinoma, Ductal, Breast / Receptor, ErbB-2 / Neoplasm Recurrence, Local Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Middle aged Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2013 Type: Article Affiliation country: Italy

Fulltext

XML

PubMed Links

Search on Google